Shamburg News · 8-K filed Nov 16, 2026, 9:29 AM EST

MapLight Therapeutics Enters $100 Million At-the-Market Sales Agreement With Leerink Partners

MPLT · MapLight Therapeutics, Inc.

  • Material agreement
  • Financing
  • Materiality: medium

On November 16, 2026, MapLight Therapeutics, Inc. entered into a Sales Agreement with Leerink Partners LLC under which it may sell shares of its common stock with an aggregate offering price of up to $100,000,000 through an at-the-market offering. The shares are being sold under a Form S-3 Registration Statement filed November 16, 2026. The Agent will receive a commission of up to 3.0% of the gross sales price per share sold, and the Company has no obligation to sell any shares.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 1.01, 9.01, accession 0001193125-26-462385.

Written from the filing by Shamburg Markets. Figures are as reported by the company.